Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis

Fig. 4

Net1 deletion inhibits RhoA activation and myosin light chain phosphorylation in tumors. a Representative examples of staining for myosin light chain 2 phosphorylated on serine 19 (pMLC2) in genotypes shown. Only solid tumors analyzed. b Quantification of pMLC2 staining as percentage of total area in genotypes shown. Seven areas analyzed, 3 animals per genotype. c Analysis of myosin phosphatase 1 (MYPT1) phosphorylation on its activating site T696 in tumor lysates. Each lane represents lysate from a tumor from a separate animal. d Analysis of active RhoA and RhoC activation in tumor lysates using GST-Rhotekin binding domain (GST-RBD) pulldowns. Each lane represents lysate from a tumor from a separate animal. e Quantification of RhoA-GTP/total RhoA for GST-RBD pulldowns. Six tumors per genotype quantified. f Quantification of RhoC-GTP/total RhoC for GST-RBD pulldowns. Six tumors per genotype quantified. g Quantification of primary tumor cell motility toward EGF in modified Boyden chambers. Data represent mean number of migrated cells/field from three separate tumors per genotype, isolated from separate mice, performed in duplicate. Errors are standard error of the mean. *P < 0.05; ***P < 0.001. GST glutathione-S-transferase, MYPT1 myosin phosphatase targeting subunit 1, Net1 neuroepithelial transforming gene 1, n.s. not significant, PyMT polyoma middle T antigen, RBD RhoA binding domain, RhoA Ras homolog family member A, RhoC Ras homolog family member C

Back to article page